Oncternal Therapeutics Past Earnings Performance
Past criteria checks 0/6
Oncternal Therapeutics's earnings have been declining at an average annual rate of -19.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
-19.4%
Earnings growth rate
41.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -9.9% |
| Return on equity | -131.4% |
| Net Margin | -5,029.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Oncternal: Solid Data In Tough-To-Treat Cancer
Jan 31Oncternal Therapeutics: Recent Success Points To A Bright Future
Jan 29Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary
Jan 14Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies
Jan 07Oncternal Therapeutics soars after presenting data at ASH
Dec 07Oncternal Therapeutics shares dip 20% after raising 'bought deal' offering to $22.5M
Nov 18Revenue & Expenses BreakdownBeta
How Oncternal Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -39 | 13 | 0 |
| 30 Sep 23 | 1 | -42 | 13 | 0 |
| 30 Jun 23 | 1 | -43 | 13 | 0 |
| 31 Mar 23 | 1 | -46 | 13 | 0 |
| 31 Dec 22 | 1 | -44 | 13 | 0 |
| 30 Sep 22 | 2 | -41 | 13 | 0 |
| 30 Jun 22 | 4 | -39 | 12 | 0 |
| 31 Mar 22 | 4 | -35 | 12 | 0 |
| 31 Dec 21 | 4 | -31 | 12 | 0 |
| 30 Sep 21 | 5 | -26 | 10 | 0 |
| 30 Jun 21 | 4 | -21 | 10 | 0 |
| 31 Mar 21 | 4 | -18 | 9 | 0 |
| 31 Dec 20 | 3 | -17 | 8 | 0 |
| 30 Sep 20 | 3 | -19 | 9 | 0 |
| 30 Jun 20 | 2 | -19 | 10 | 0 |
| 31 Mar 20 | 3 | -37 | 9 | 0 |
| 31 Dec 19 | 2 | -34 | 7 | 0 |
| 30 Sep 19 | 2 | -31 | 5 | 0 |
| 30 Jun 19 | 2 | -28 | 3 | 0 |
| 31 Mar 19 | 3 | -7 | 2 | 0 |
| 31 Dec 18 | 3 | -7 | 2 | 0 |
| 31 Dec 17 | 2 | -10 | 3 | 0 |
Quality Earnings: ONCT is currently unprofitable.
Growing Profit Margin: ONCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONCT is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.
Accelerating Growth: Unable to compare ONCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ONCT has a negative Return on Equity (-131.37%), as it is currently unprofitable.